Edition:
United States

BioDelivery Sciences International Inc (BDSI.OQ)

BDSI.OQ on NASDAQ Stock Exchange Capital Market

2.25USD
4:00pm EDT
Change (% chg)

$-0.05 (-2.17%)
Prev Close
$2.30
Open
$2.30
Day's High
$2.30
Day's Low
$2.20
Volume
46,321
Avg. Vol
58,801
52-wk High
$3.60
52-wk Low
$1.70

Chart for

About

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products... (more)

Overall

Beta: 0.52
Market Cap(Mil.): $134.43
Shares Outstanding(Mil.): 58.45
Dividend: --
Yield (%): --

Financials

  BDSI.OQ Industry Sector
P/E (TTM): -- 28.57 32.53
EPS (TTM): -0.96 -- --
ROI: -81.36 13.08 12.63
ROE: -271.67 14.80 14.50

BRIEF-BioDelivery Sciences Announces Agreement With Broadfin Capital On Comprehensive Plan To Strengthen Business

* BIODELIVERY SCIENCES ANNOUNCES AGREEMENT WITH BROADFIN CAPITAL ON COMPREHENSIVE PLAN TO STRENGTHEN BUSINESS

May 17 2018

BRIEF-Biodelivery Sciences Reports Q1 Loss Per Share $0.18

* BIODELIVERY SCIENCES REPORTS POSITIVE FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 10 2018

BRIEF-BioDelivery Sciences Appoints Herm Cukier As CEO

* BIODELIVERY SCIENCES APPOINTS HERM CUKIER AS CHIEF EXECUTIVE OFFICER

May 07 2018

BRIEF-Broadfin Says Delivered Letter To BioDelivery Sciences With Nominations For Board

* BROADFIN - ON APRIL 27, DELIVERED LETTER TO BIODELIVERY SCIENCES NOMINATING TODD C. DAVIS, PETER S. GREENLEAF, STEPHEN T. WILLS FOR ELECTION TO BOARD

May 01 2018

BRIEF-Broadfin Capital Reports 7.3 Pct Stake In Biodelivery Sciences

April 10 BioDelivery Sciences International Inc :

Apr 10 2018

BRIEF-Biodelivery Sciences Reports Q4 Loss Per Share $0.29

March 15 Biodelivery Sciences International Inc :

Mar 15 2018

BRIEF-Biodelivery Sciences Announces Belbuca Patent Litigation Settlement Agreement With Teva

* BIODELIVERY SCIENCES ANNOUNCES BELBUCA PATENT LITIGATION SETTLEMENT AGREEMENT WITH TEVA

Feb 06 2018

BRIEF-BioDelivery Sciences Announces Launch And Availability Of Belbuca In Canada

* BIODELIVERY SCIENCES ANNOUNCES LAUNCH AND AVAILABILITY OF BELBUCA® IN CANADA Source text for Eikon: Further company coverage:

Jan 30 2018

BRIEF-BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical

* BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL

Dec 14 2017

BRIEF-BioDelivery Sciences Says ‍Ohio Workers Compensation Approved Change To Formulary

* BIODELIVERY SCIENCES - ‍OHIO BUREAU OF WORKERS COMPENSATION APPROVED CHANGE TO ITS FORMULARY RESULTING IN FAVORABLE POSITIONING FOR BELBUCA, BUNAVAIL

Nov 27 2017

Earnings vs. Estimates